PURPOSE. Several single-nucleotide polymorphisms (SNPs) in the C2 and BF genes have been associated with age-related macular degeneration (AMD) in Caucasian populations from the United States. The study was conducted to evaluate whether these SNPs are also associated with AMD in persons of Anglo-Celtic ethnicity in an Australian population. METHODS. Included in the study were 565 persons with AMD and 204 ethnically matched control subjects. All participants completed a standard health questionnaire, were given a fundus examination, and provided a blood sample for DNA extraction. Alleles were determined by a matrix-assisted desorption ionization-time of flight (MALDI-TOF)-based approach followed by statistical analysis. RESULTS. The C2 and BF genes indicated significant association with AMD of only two SNPs; rs547154 (IVS10) in the C2 gene (P ϭ 9.1 ϫ 10 Ϫ5 ) and rs641153 (R32Q) in the BF gene (P ϭ 7.0 ϫ 10 Ϫ5 ). No association with AMD was found for SNP rs9332739 (E318D) in the C2 gene or for rs4151667 (L9H), rs1048709 (R150R), rs4151659 (K565E), or rs2072633 (IVS17) in the BF gene. A protective haplotype of variants IVS10 and R32Q was associated with AMD (OR 0.29, 95% CI 0.20 -0.42). CONCLUSIONS. In this study, the association of the IVS10 and R32Q variants in the C2 and BF genes in AMD was replicated. Haplotype analysis indicated association of these variants with AMD in an Australian population. Both IVS10 and R32Q variants were in strong linkage disequilibrium with each other (r 2 ϭ 0.96). Although the E318D and L9H variants have shown association with AMD in previous studies, the findings were not in agreement. This demonstrates a refined pattern of association of these rare variants with AMD. (Invest Ophthalmol Vis Sci. 2009;50:540 -543) DOI:10.1167/iovs.08-2423 A ge-related macular degeneration (AMD) (ARMD1; MIM 603075) is the leading cause of uncorrectable vision loss and blindness in developed countries, and in Australia it contributes to up to 50% of all blindness (presenting visual acuity Ͻ 6/60).
ge-related macular degeneration (AMD) (ARMD1; MIM 603075) is the leading cause of uncorrectable vision loss and blindness in developed countries, and in Australia it contributes to up to 50% of all blindness (presenting visual acuity Ͻ 6/60). 1 A genetic predisposition to this disease has clearly been shown with several genes having now been identified, of which several are inflammatory genes, including the complement factor H gene and the C3 gene of the alternative pathway. [2] [3] [4] [5] [6] Additional support for the involvement of an inflammatory involvement in AMD comes from the association of the two paralogous genes complement component 2 (C2; MIM 217000) and factor B (BF; MIM 138470), located within the gene-rich class III region of the HLA complex on chromosome 6. [7] [8] [9] Moreover, BF and C2 are involved in the initiation of the alternative complement cascade and the activation of the classic component pathway, respectively.
In three previous studies based on American case control cohorts, with one including a family study, 9 the association of the C2 and BF genes with AMD has been examined. [7] [8] [9] In two of these studies, the AMD subtypes of early geographic atrophy (GA) and choroidal neovascular (CNV) AMD were investigated. 7, 9 The third study was performed to investigate only late-stage AMD. 8 These reports consistently showed involvement of several single-nucleotide polymorphisms (SNPs), including E318D and IVS10 of the C2 gene and L9H and R32Q of the BF gene, with AMD. Each study held the consensus view that each of these SNPs is involved in protection against AMD.
The purpose of our study was to undertake a replication of work on previously identified SNPs in the C2 and BF genes in an Australian AMD case-control cohort, to investigate the SNPs' involvement in AMD.
METHODS

Subjects
All individuals in this study were a part of our AMD Inheritance Study (AMDIS). All individuals with AMD were identified through either outpatient clinics at the Royal Victorian Eye and Ear Hospital (RVEEH) or private ophthalmology practices in Melbourne and had an AngloCeltic ethnic background. Individuals with AMD were included if they had drusen Ͼ 125 m. Control subjects were obtained from the same community as part of a large population-based epidemiologic eye study, the Melbourne Visual Impairment Project (VIP) or through aged-care nursing homes. Control individuals were included if they presented with a normal fundus (Ͻ10 hard drusen Ͻ63 m in size) and no altered macular pigmentation. At the time of ascertainment a clinical examination was performed, a fundus photograph obtained, and a blood sample collected for DNA analysis. In addition, all participants completed a standard risk factor and disease history questionnaire. Smoking was assessed by asking whether individuals were current or past smokers or had never smoked. All participants in our study were unrelated.
Written informed consent was obtained from all individuals, and ethics approval for the project was provided by the Human Research and Ethics Committee of the Royal Victorian Eye and Ear Hospital, Melbourne. The study was conducted in accordance with the Declaration of Helsinki and according to the National Health and Medical Research Council of Australia's statement on ethical conduct in research involving humans, revised in 1999.
gene, and rs4151667 (L9H), rs641153 (R32Q), rs1048709 (R150R), rs4151659 (K565E), and rs2072633 (IVS17) in the BF gene.
Genotyping of all SNPs was performed as previously described 10 using a genetic analysis system (MassARRAY platform; Sequenom, San Diego, CA) through the Australian Genome Research Facility (AGRF; Brisbane, Australia). The polymerase chain reaction (PCR) primers and primers (MassExtend; Sequenom) used in our study are listed in Table 1 .
Statistical Analysis
Study characteristics including sex and age at ascertainment or diagnosis of the participants with and without AMD were compared by using the 2 test or independent sample t-test. Hardy-Weinberg equilibrium (HWE) was undertaken to assess whether genotypes fell within a standard distribution with the software program JLIN: a Java-based linkage disequilibrium (LD) plotter. 11 Deviations of genotype frequencies in controls and cases from those expected under Hardy Weinberg were assessed by 2 tests. Allelic associations with AMD were investigated with the UNPHASED software, 12 and results were presented as odds ratio (OR; 95% [confidence interval] CI). Genotype frequencies were compared between total AMD cases and controls and also between AMD subtypes and controls by 2 . We applied the additive model as the best-fit model to determine genotype distributions. Haplotype analysis was performed by using the same UNPHASED software. 12 Participants' characteristics and genotype associations were performed with commercial software (SPSS; ver. 14.0; SPSS Inc., Chicago, IL).
RESULTS
A total of 769 individuals were included in this study. Of these, 565 (73%) individuals presented with AMD with a mean age of diagnosis of 73.4 years. In addition, 204 (27%) unaffected individuals with a similar mean age of 72.4 years were also recruited (P ϭ 0.1; Table 2 ). There were significantly more females with AMD than there were males, and a higher percentage of females overall compared with males (P Ͻ 0.02; Table 2 ).
There was no evidence of departure from HWE for any of the SNPs analyzed in our study (P Ͼ 0.05; data not shown). Allelic association, after adjustment for smoking, was evident for AMD for the variant IVS10 of the C2 gene, with an OR of 2.28 (95% CI, 1.52-3.40) and for the variant R32Q of the BF gene with an OR of 2.31 (95% CI, 1.55-3.45; Table 3 ). We did not detect any significant allelic association for the variant E318D in the C2 gene, nor for the variants L9H, R150R, K565E, and IVS17 in the BF gene ( Table 3) .
The genotype distribution in total AMD and control for all SNPs was compared by using 2 statistics. In genotype associations, only IVS10 and R32Q were significantly associated with AMD, as was observed in allelic associations (Table 3) . After Bonferroni correction for multiple testing, both IVS10 and R32Q variants remained significant in AMD cases compared with controls (P Յ 0.001; Table 3 ).
AMD subtype association analysis was not undertaken, as none of the subtypes was significantly different than the total AMD group in their observed genotype frequencies.
Haplotype analysis revealed only one haplotype (haplotype 2) as being significantly associated with protection against AMD with an odds ratio of 0.29 (Table 4) . No other haplotype combinations were found to be significant in our analysis (Table 4) .
DISCUSSION
This is the first non-U.S. Caucasian study in which the association of SNP variants in the C2 and BF genes in AMD was examined. In the present study we confirmed previous significant findings for the two SNPs, IVS10 in the C2 gene and R32Q in the BF gene, in association with AMD.
The IVS10 and R32Q variants appear to be in complete LD (r 2 ϭ 0.96) in our AMD cohort (Fig. 1) . These findings agree with previous studies that showed these two variants to be in strong LD. [7] [8] [9] However, R32Q was not in LD with any of the other SNPs tested in this study. Previous studies also implicated the E318D and L9H variants in the C2 and BF genes, respectively, as being associated with AMD as well as being in high LD with each other. [7] [8] [9] Although we did find them to be in high LD (r 2 ϭ 0.97), our findings do not support their association with AMD. A previous report also indicated no significant association of the E318D and L9H variants in the family arm of their study or when smoking was included as a covariant in their case-control model. 9 Overall, these findings suggest that the protective effect of the C2 and BF genes resides within the LD block identified by the IVS10 and R32Q variants.
The protective alleles (T at IVS10 and A at R32Q) present as uncommon variants in our study with a frequency of 0.117 and for IVS10 and R32Q between controls and cases has been reported in prior studies. [7] [8] [9] As a consequence, we were only able to detect a TT genotype for IVS10 or an AA genotype for R32Q in 3/204 (1.5%) of controls and 2/565 (0.3%) cases of AMD. The level of association in the IVS10 and R32Q variants is highlighted by our haplotype analysis. Haplotype 2 showed the protective effect of the changes at both these variants. This finding is in agreement with the original paper by Gold et al., 7 outlining the association of the C2 and BF genes with AMD.
One of the main challenges in identifying genetic variants in complex diseases using genome-wide association studies (GWAS) is to identify not only common but also rare variants that have small but important roles in disease etiology. 13 The evidence presented herein suggests that the variants in the C2/BF genes associated with AMD clearly fall into this rare variant category. It is, therefore, likely that other rare genetic variants exist that also play a role in AMD, and these are as yet to be identified either through linkage or GWAS.
In summary, our data further refine the causative variant for AMD to the LD block identified by either IVS10 in the C2 gene or the R32Q in the BF gene. This observation, along with previous reports that have narrowed the variants to be either E318D or IVS10 in the C2 gene and L9H or R32Q in the BF gene, indicates that IVS10 and R32Q have remained candidate variants associated with AMD throughout all the studies conducted to date. However, our inability to replicate the E318D-or L9H-associated variants identified in the U.S. studies indicates one of the key challenges faced by the Human Variome Project 14 in establishing the role of rare variants in what appear to be similar but subtly different in Caucasian populations in the United States and Australia. 
